PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Novel Biomaterials Accelerate the Development of Innovative Wound Care Management Technologies Finds Frost & Sullivan - Modern wound management focuses on improving the wound healing mechanism to enhance the patient's quality of life - TechnicalInsights.Frost.com
Novel Biomaterials Accelerate the Development of Innovative Wound Care Management Technologies Finds Frost & Sullivan

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2013/02/20 - Modern wound management focuses on improving the wound healing mechanism to enhance the patient's quality of life - TechnicalInsights.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

New wound care technologies that detect early wound healing and manage wound healing mechanisms are finding favor with physicians that are trying to determine suitable treatment protocols. Wound care management received a thrust from cost-effective and efficient technologically advanced products and therapies. Some wound care advancements that gained traction recently include wound dressings that offer controlled release of enzymes and antimicrobial agents, and silver nanocomposites that exhibit protective barrier and anti-inflammatory properties.

New analysis from Frost & Sullivan's (technicalinsights.frost.com) Wound Care Management Technologies research finds that wound care therapy developers are increasingly responding to the demand for more effective wound care solutions. Biotechnology, biomaterial, and tissue engineering-enabled innovations are some of the fastest growing technology segments in this market.

If you are interested in more information on this research, please email Britni Myers, Corporate Communications, at britni.myers[.]frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

Other popular innovations in wound management include honey-based dressings with antimicrobial, wound cleansing, and pain-free debridement properties, as well as tissue engineering constructs to promote wound healing. Combination medical devices that help deliver targeted wound care therapy to ensure safe and timely closure of wounds are also in demand.

Wound care specialists and podiatrists as well as general, vascular and orthopedic surgeons prefer cost-effective wound care solutions, while chronic wound patients and their caregivers seek faster and long-lasting wound healing solutions. Reacting to customer demand, manufacturers are adopting best practices to design wound dressings that provide tight control over the dressing's adsorption and fluid handling properties.

There is a surge in the number of wound healing technology platforms awaiting commercialization and multiple start-up firms and spin-offs from academia are working on procuring funds and partnerships for commercialization. Both Tier 1 and emerging companies are engaged in intense R&D to develop dressings that accelerate healing.

"Emerging companies that focus on every type of wound at each phase of the wound healing process will be able to provide innovative solutions," noted Frost & Sullivan Technical Insights Industry Analyst Prasanna Vadhana Kannan. "One of the noteworthy wound care solutions are advanced wound dressings that can assist in the complex task of tissue repair and efficiently remove bacterial biofilm formation."

Currently, there are no national or international standards to guide wound care dressing manufacturers, and the type of protocol adopted depends upon the physician's recommendation and patient's demand. This situation hinders the implementation and testing of affordable wound care platforms.

Standardization is vital since wound treatment relies heavily on proper wound bed preparation, the choice of wound dressings, and the patient's condition. Wound closure also depends on the use of appropriate products.

Researchers are striving to examine the importance of cell differentiation and tissue morphogenesis-based factors in faster wound healing. Manufacturers need greater clinical evidence to understand biological-mediated therapies and their role in improving the outcome of wound care.

"On the back of considerable research, wound care solutions are expected to have the capabilities to safeguard cells from apoptosis, and simultaneously stimulate rapid cell division and proliferation," noted Kannan. "A rising desire to achieve tissue regeneration rather than just wound closure encourages manufacturers to explore additional applications of wound healing technologies."

Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare, and LinkedIn, for the latest news and updates.

Wound Care Management Technologies, a part of the Technical Insights subscription, analyzes advances in the application of silver in microbial prophylaxis and treatment, advanced wound dressings and skin substitutes, biologic wound products, and hyperbaric oxygen as an adjunctive wound care treatment. Further, this research service includes detailed technology analysis and industry trends evaluated following extensive interviews with market participants.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters and research services.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360-degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation

Wound Care Management Technologies / D4BE-54

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novel Biomaterials Accelerate the Development of Innovative Wound Care Management Technologies Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Britni Myers 
210-477-8481 britni.myers[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)